Safety of presurgical targeted therapy in the setting of metastatic renal cell carcinoma - Wikidata - awgldk - TriplyDB

Safety of presurgical targeted therapy in the setting of metastatic renal cell carcinoma

Safety of presurgical targeted therapy in the setting of metastatic renal cell carcinoma

http://www.wikidata.org/entity/Q35230659

about

The role of neoadjuvant therapy in the management of locally advanced renal cell carcinoma Cytoreductive surgery in the era of targeted molecular therapy Cytoreductive nephrectomy and its role in the present-day period of targeted therapy.Neoadjuvant therapy of renal cell carcinoma: a novel treatment option in the era of targeted therapy?Surgical Management of Advanced and Metastatic Renal Cell Carcinoma: A Multidisciplinary Approach.Surgical management of renal cell carcinoma: Canadian Kidney Cancer Forum Consensus.Presurgical therapy with axitinib for advanced renal cell carcinoma: a case report.Cytoreductive nephrectomy for metastatic renal cell carcinoma in the era of targeted therapy in the United States: a SEER analysis.Trends in the use of cytoreductive nephrectomy in the United States.Comprehensive characterization of the perioperative morbidity of cytoreductive nephrectomy.Targeted therapies in metastatic renal cell carcinoma: overview of the past year.Selecting patients for cytoreductive nephrectomy in advanced renal cell carcinoma: who and when.Neoadjuvant treatment in advanced renal cell carcinoma: current situation and future perspectives.The role of surgery for metastatic renal cell carcinoma in the era of targeted therapies.Recent advances in the treatment of metastatic renal cell carcinoma.Advanced kidney cancer: treating the elderly.Surgical management of metastatic renal cell carcinoma in the era of targeted therapies.Extracranial oligometastatic renal cell carcinoma: current management and future directions.New challenges in kidney cancer management: integration of surgery and novel therapies.Treatment strategies for advanced renal cell carcinoma: A new paradigm for surgical treatment.Presurgical neoadjuvant targeted molecular therapy for kidney cancer with concomitant vena cava tumor embolus: A clinical study.Renal cell cancer: what can we learn from pre-operative studies?Cytoreductive nephrectomy for metastatic renal cell carcinoma: a population-based analysis of perioperative outcomes according to clinical stage.Metastasectomy following incomplete response to high-dose interleukin-2.Effective downsizing but enhanced intratumoral heterogeneity following neoadjuvant sorafenib in patients with non-metastatic renal cell carcinoma.Efficacy of pre-surgical axitinib for shrinkage of inferior vena cava thrombus in a patient with advanced renal cell carcinoma.Surgical Complications of Presurgical Systemic Therapy for Renal Cell Carcinoma: A Systematic Review

P2860

Q26749084-0A39827A-9A62-4B69-91A2-C98A4755B512 Q26774134-01B9A494-2E1C-42EB-87CD-CB6F01BCEA14 Q26783520-EDA8DB9F-8645-4917-801F-931377549BF6 Q27002583-AF1BA7DA-C14A-4169-B9C5-E07E524EC57E Q33740717-978EE948-90BC-412D-AF63-B5128EEE87EF Q33843677-17CB396B-8228-4D28-905E-2831768FBE3F Q35051078-E9C44209-FECB-4857-8F46-62DD1C822581 Q36553493-438EDB35-9E8A-452D-894F-59378905B1BC Q36553501-C852B5DD-7EA4-4642-997C-B7DB6EE5E389 Q36969971-A9884903-F22E-4690-BE24-773FEF5A8075 Q37964565-2ABC3A50-A2A0-49D2-A5D2-E839283388DA Q38020245-D4C3B69D-BF8C-4E95-8ED5-CBC009163EC8 Q38068585-F969F52E-3663-4026-82EF-E002AABE63E3 Q38094592-A97E7377-DC7C-495E-9B11-0286C2E0CA96 Q38108392-B3124BED-8164-4BE4-9A04-F5A40CE3540C Q38162249-549C2CF4-3C20-493D-9661-5603AAF8F405 Q38202061-5D639F72-178C-4C18-BF5D-D25ED577C4C5 Q38209605-05E1BEB3-8FF5-47BF-B8E0-92A9BCEF401F Q38381788-593CF1D6-879D-48FB-92BF-7CA9101E90D2 Q38582600-AA2EC37B-E489-490D-A98F-C85978BADEF0 Q40977445-BC14BDFD-653C-432D-A625-CDBD7167F9BE Q42175050-AD77E2D4-66AA-43A3-AC66-2EC24C815D31 Q44217603-8A020DA8-B3FF-4D8A-9478-15542C5D90D4 Q47428650-57ECC51B-0D40-4F06-9873-BB048E3A7FF4 Q52936751-16482026-695A-4241-9F1C-ABB5EF4EF26C Q54374819-3094D4FC-5995-40DE-BBDC-474B539C09AF Q58585062-CD526AD7-83B7-4792-B482-80D5FE454569

P2860

Safety of presurgical targeted therapy in the setting of metastatic renal cell carcinoma

http://www.wikidata.org/entity/Q35230659

description

2011 nî lūn-bûn

@nan

2011 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Safety of presurgical targeted therapy in the setting of metastatic renal cell carcinoma

@ast

Safety of presurgical targeted therapy in the setting of metastatic renal cell carcinoma

@en

type

label

Safety of presurgical targeted therapy in the setting of metastatic renal cell carcinoma

@ast

Safety of presurgical targeted therapy in the setting of metastatic renal cell carcinoma

@en

prefLabel

Safety of presurgical targeted therapy in the setting of metastatic renal cell carcinoma

@ast

Safety of presurgical targeted therapy in the setting of metastatic renal cell carcinoma

@en

P1433

Q35230659-8C0881F4-E26F-4668-8F07-4F9AEEA3B123

P1476

Q35230659-621DD750-05AF-4702-B0FD-A3D134B9B890

P2093

Q35230659-6BD4D443-067C-44E3-9D50-88C6B3AAFF22

Q35230659-7C9CB097-ECA6-44DF-B3EF-1D190F486771

Q35230659-7DEFA714-EC45-44E1-8FEC-A14CB12E5BE2

Q35230659-B520A527-94CC-4744-8E75-28561369E77A

Q35230659-B84F589E-BD91-4E71-890C-51AC610DD771

Q35230659-BDD10264-EBD8-4A18-9176-CFAF01804831

Q35230659-C5C336D9-FF8F-43E2-8084-054DBBDF860C

Q35230659-F151FC21-B9AF-4CFB-978B-9B1BEA1F713B

P2860

Q35230659-099EAACA-75B5-4A25-854C-25FCD47B9C36

Q35230659-1F50CB72-94ED-42EB-8C22-A15912974114

Q35230659-26A02C6A-1869-4D62-B71F-57100E0D667D

Q35230659-27FF8E5E-37A6-4470-8D76-85AAA2BA126D

Q35230659-4E3B0760-AE64-4E40-A30E-56C055DCCC25

Q35230659-54A5B7BC-4080-4A7B-B233-F71776A0C5A8

Q35230659-5E9415B8-D747-4E4D-91DC-443777BE7765

Q35230659-7B45B858-3741-4980-B8FF-5044CCD4C63B

Q35230659-94547963-66F4-4FBF-AA88-DA9EB1AE17B6

Q35230659-9C077EC5-A4FE-499C-B95B-EB28844BFBC7

P304

Q35230659-92C815F9-B467-46BB-9E6C-D7C9452585BB

P31

Q35230659-3C4A1A0D-1F23-4B47-B379-6A3FFC9DB1DA

P356

Q35230659-7EA6AC1D-2C75-48CD-8FB8-032E7D7BFF65

P407

Q35230659-0F1433CD-025A-4BC3-AE11-FAC80448CAF9

P433

Q35230659-5E32D395-DA3A-4AE5-8815-BB9F878F930A

P478

Q35230659-025970D5-D767-45CB-9361-3D7D50EF8748

P577

Q35230659-03D3DF91-009F-476F-AED5-5D2CB735572B

P5875

Q35230659-E6C18C19-AC30-4E1F-8ED4-BC0570CCF35E

P698

Q35230659-8EED5782-8A63-4034-BF1B-6A1F47EB8444

P932

Q35230659-E5C1C305-7373-45FB-8D03-E315F6D88A39

P356

J.EURURO.2011.05.032

P1433

European Urology

P1476

Safety of presurgical targeted therapy in the setting of metastatic renal cell carcinoma

@en

P2093

Brian F Chapin

http://www.w3.org/2001/XMLSchema#string

Christopher G Wood

http://www.w3.org/2001/XMLSchema#string

Eric Jonasch

http://www.w3.org/2001/XMLSchema#string

Graciela M Nogueras Gonzalez

http://www.w3.org/2001/XMLSchema#string

Nizar M Tannir

http://www.w3.org/2001/XMLSchema#string

Pheroz Tamboli

http://www.w3.org/2001/XMLSchema#string

Scott E Delacroix

http://www.w3.org/2001/XMLSchema#string

Stephen H Culp

http://www.w3.org/2001/XMLSchema#string

P2860

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey

Preoperative serum carcinoembryonic antigen, albumin and age are supplementary to UICC staging systems in predicting survival for colorectal cancer patients undergoing surgical treatment.

Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial.

Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer.

Effect of preoperative nutritional deficiency on mortality after radical cystectomy for bladder cancer

Preoperative nutritional status is an important predictor of survival in patients undergoing surgery for renal cell carcinoma.

Prospective clinical trial of preoperative sunitinib in patients with renal cell carcinoma.

Phase II presurgical feasibility study of bevacizumab in untreated patients with metastatic renal cell carcinoma.

Standards for surgical complication reporting in urologic oncology: time for a change.

P304

964-971

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.EURURO.2011.05.032

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

60

http://www.w3.org/2001/XMLSchema#string

P577

2011-05-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51174081

http://www.w3.org/2001/XMLSchema#string

P698

21621907

http://www.w3.org/2001/XMLSchema#string

P932

4378825

http://www.w3.org/2001/XMLSchema#string